Dicerna Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc (DRNA): 7 pipeline candidates · ~14 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.0 months
D/E 6.17 · 0% dilution
Lead: Phase 3
7 candidates
N/A
N/A
A transparent, data-derived signal for Dicerna Pharmaceuticals Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$171.4M
Quarterly Burn
$63.8M
Runway
14.0 mo
Revenue
$63.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Frequently asked questions
How many drug candidates are in Dicerna Pharmaceuticals Inc's pipeline?
Dicerna Pharmaceuticals Inc (DRNA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Dicerna Pharmaceuticals Inc's lead drug candidate?
Dicerna Pharmaceuticals Inc's most advanced tracked candidate is belcesiran (Phase 2) for Alpha 1-Antitrypsin Deficiency.
What is Dicerna Pharmaceuticals Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Dicerna Pharmaceuticals Inc has approximately 14.0 months of cash runway.
Who is the CEO of Dicerna Pharmaceuticals Inc?
Massachusetts April is the chief executive officer of Dicerna Pharmaceuticals Inc (DRNA).
Get the full picture on Dicerna Pharmaceuticals Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.